A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma

Inclusion Criteria: * Participants must have clinical diagnosis of cutaneous T-cell lymphoma or peripheral T-cell lymphoma with cutaneous involvement supported by histological evaluation of skin lesions. * Participants must have measurable cutaneous disease, based on the modified Severity Weighted Assessment Tool (mSWAT; definition provided in appendix E). Skin lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. * Two lesions are amenable to placement of multiple devices in terms of lesion size and location, as assessed by dermatologist (minimum diameter of 1.5 cm). * Patient must have the following minimum washout period from previous treatments and cannot be on any systemic therapy at the time of implantation. * 2 week from topical therapies of lesional skin selected for implantation * 2 weeks from retinoids, interferons, vorinostat, romidepsin, therapeutic doses of oral corticosteroids (physiologic replacement doses of oral corticosteoids are allowed) * 4 weeks from phototherapy * 5 half-lives for systemic cytotoxic anticancer agents, monoclonal antibodies, and investigational therapy * 12 weeks from local radiation therapy of lesional skin selected for implantation * 15 weeks from systemic immunotherapy targeting PD-1/PD-L1 * Age minimum of age 18. * ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A). * Participants will undergo laboratory testing within 28 days prior to th…